Biotechnology

AFFIMED N V

AFFIMED N V released FY2024 Q3 earnings on November 14 (EST), actual revenue USD 183.12 K (forecast USD 1.39 M), actual EPS USD -1.0499

AFFIMED N V released FY2024 9 Months earnings on November 14 (EST), actual revenue USD 766.34 K, actual EPS USD -3.4992

AFFIMED N V released FY2023 9 Months Earnings on November 14, 2024 (EST) with actual revenue of USD 9.712 M and EPS of USD -6.1955

AFFIMED N V released FY2023 Q3 earnings on November 14 (EST), actual revenue USD 2.072 M (forecast USD 2.024 M), actual EPS USD -1.7277

AFFIMED N V released FY2024 Semi-Annual earnings on September 5, 2024 (EST), with actual revenue of USD 582.74 K and EPS of USD -2.4472

AFFIMED N V released FY2023 Q2 earnings on September 5, 2024 (EST), actual revenue USD 2.289 M (forecast USD 4.759 M), actual EPS USD -2.1387

AFFIMED N V released FY2024 Q2 earnings on September 5 (EST), actual revenue USD 224.96 K (forecast USD 1.247 M), actual EPS USD -1.0817

AFFIMED N V released FY2023 Semi-Annual earnings on September 5, 2024 (EST) with actual revenue of USD 7.643 M and EPS of USD -4.47

AFFIMED N V released FY2024 Q1 earnings on June 12 (EST), actual revenue USD 358.26 K (forecast USD 1.034 M), actual EPS USD -1.3675

AFFIMED N V released FY2023 Q1 earnings on June 12 (EST), actual revenue USD 5.351 M (forecast USD 6.2 M), actual EPS USD -2.329

Treasure Gbl

SMX Security Matters

Wheeler Real Estate

Gulf Resources

DigitalBridge

Toro

Dreamland

Lichen

Springview

Alumis

Adma Biologics

Kiniksa Pharmaceuticals

Stoke Therapeutics

Rigel Pharma

OpGen

Vertex Pharma

Regeneron Pharma

Alnylam Pharma

Argenx

Beigene

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap